Does Wegovy Cause Gallbladder Stones?
Wegovy (semaglutide), a GLP-1 receptor agonist for weight loss, carries a risk of gallbladder-related issues, including gallstones (cholelithiasis). Clinical trials and post-marketing data show higher rates of cholelithiasis and cholecystitis in patients using semaglutide compared to placebo. In the STEP 1 trial, 2.6% of Wegovy users (2.4 mg dose) developed cholelithiasis versus 1.2% on placebo, with similar patterns in other STEP trials.[1][2]
The label warns of gallbladder disease risk, advising monitoring for symptoms like abdominal pain, nausea, or jaundice.[3]
How Does Wegovy Increase Gallstone Risk?
Rapid weight loss from Wegovy slows gallbladder emptying (reduced motility), promoting bile stasis and stone formation. GLP-1 drugs like semaglutide also alter bile composition. This mirrors risks with other weight-loss drugs; incidence rises with dose and duration, peaking after 6-12 months.[1][4]
What Do Real-World Studies Show?
Post-approval data from over 2 million semaglutide users (including Ozempic) report gallbladder disorders in 1-2% of cases, with some needing cholecystectomy. A 2023 Danish study found 1.5 times higher cholecystectomy risk versus non-users, adjusted for obesity.[5] FDA adverse event reports list thousands of gallstone cases linked to semaglutide.[6]
Who Is Most at Risk?
Women, those over 40, with prior gallstones, or losing >5% body weight quickly face higher odds. Obesity itself raises baseline risk (20-30% prevalence), but Wegovy adds 1.5-2x multiplier.[2][4]
What Symptoms Should You Watch For?
Sudden right-upper abdominal pain, fever, vomiting, or bloating signal issues. Seek immediate care; 20-30% of symptomatic gallstones lead to complications like infection.[3][7]
Treatment and Management
Mild cases may resolve with dose reduction or pausing therapy. Severe ones require surgery (laparoscopic cholecystectomy). Guidelines recommend ultrasound screening for high-risk patients before or during treatment.[1][8]
How Does This Compare to Other Weight-Loss Drugs?
| Drug | Gallstone Risk Increase | Notes |
|------|--------------------------|-------|
| Wegovy (semaglutide) | 1.5-2x vs placebo | Dose-dependent[1] |
| Saxenda (liraglutide) | Similar, 2-3% incidence[9] | Same GLP-1 class |
| Phentermine | Lower, <1%[10] | Shorter-term use |
| Orlistat | Minimal[11] | Different mechanism |
Can You Prevent Gallstones on Wegovy?
Lose weight gradually (<2 lbs/week), stay hydrated, eat high-fiber/low-fat meals to aid motility. Prophylactic ursodiol is sometimes used off-label in high-risk cases.[4][8]
[1]: NEJM STEP 1 Trial (2021)
[2]: Novo Nordisk STEP Program Data
[3]: FDA Wegovy Label
[4]: JAMA Network Open (2023)
[5]: Diabetes, Obesity and Metabolism (2023)
[6]: FDA FAERS Database
[7]: Mayo Clinic Gallstones Overview
[8]: AACE Obesity Guidelines (2022)
[9]: FDA Saxenda Label
[10]: FDA Phentermine Label
[11]: FDA Xenical Label